

Prevalence and Risk Factors of Hepatitis C Infection (HCV) in Birjand, Iran, 2014

Azade Ebrahimzadeh,¹ Zohreh Azarkar,^{1*} Masood Ziaee,¹ Gholamreza Sharifzadeh,¹ and Bita Bijari¹

¹Birjand Hepatitis Researches Center, Birjand University of Medical Sciences, Birjand, IR Iran

*Corresponding author: Zohreh Azarkar, Birjand Hepatitis Researches Center, Birjand University of Medical Sciences, Birjand, IR Iran. Tel: +98-56324430009; +98-9151613920, Fax: +98-5632445402, E-mail: drz.azarkar@yahoo.com

Received 2015 October 31; Revised 2015 November 11; Accepted 2015 November 14.

Abstract

Background: Hepatitis C virus (HCV) infection is an important global concern, with a frequency of 3% (i.e., 170 million of the population has HCV-Ab). Additionally, 50% of HCV and 80% of transfusion transmitted infections (TTI) are chronic. In 20% of cases, HCV occurs as an acute infection, and in the remaining 80% of cases, it becomes chronic. In chronic patients, risk of cirrhosis is up to 44%, risk of hepatocellular carcinoma (HCC) is 13%, and risk of mortality is 14%. As there is no vaccine available for the virus yet, and since most of the cases are asymptomatic, attention to the epidemiology of the disease among the population is a pressing concern.

Objectives: The aim of this study is to determine the prevalence and risk factors of HCV in Birjand city.

Patients and Methods: In this descriptive-analytical study, 5,235 people who live in Birjand city were selected; after gaining permission for the study, a signed consent form was obtained from each patient. Prevalence of HCV was determined by ELISA test, and positive cases underwent Polymerase chain reaction (PCR) and genotyping for confirmation.

Results: The mean age of the participants was 39.7 ± 14.4 . Among them, 52.2% were female and 29.9% had university degrees. Prevalence of HCV-Ab⁺ was about 0.2% with ELISA, and 0.14% of entire group were confirmed by PCR. No significant relationship was found for age, sex, and education ($P > 0.05$). Also, there was no significant relationship found with risk factors such as endoscopy, blood transfusion, surgery, hospitalization, phlebotomy, and alcohol drinking ($P > 0.05$). HCV-Ab was 200 times more prevalent in IV-drug abusers compared to non-addicted people. Also, the prevalence of HCV-Ab in non-IV-drug abuser addicts was 9.3 times higher than in non-addict patients. Prevalence of HCV-Ab in patients who reported illicit sexual activities was 13.3 times higher. In patients with a familial history of HCV, infection was 26.3 times more prevalent than in patients with no familial history ($P < 0.001$).

Conclusions: In this study, the prevalence of HCV was 0.2%, which is lower than the mean prevalence in Iran (1%). Prevalence of HCV had a significant relationship with IV-drug abuse.

Keywords: Prevalence, Hepatitis C (HCV), Risk Factors

1. Background

Hepatitis C virus (HCV) is an enveloped, single-stranded RNA virus that represents a major health problem in the world and is prevalent among chronic liver diseases. It has been estimated that HCV accounts for 27% of cirrhosis and 25% of hepatocellular carcinoma (HCC) worldwide (1).

The estimated prevalence of HCV infection is 2.2%, or about 170 million positive persons around the world. One study showed that prevalence ranges from a low of $< 1\%$ in Scandinavia in northern Europe (0.01 – 0.1) to a high of $> 3\%$ in Egypt in northern Africa (15 – 20%) (2). Risk factors associated with HCV are the transfusion of blood and its products, the use of injected street drugs or IVDU, accidental injections, birth to an infected mother, sexual contact, and illicit sexual activities (2). Among that population, 48.4% were IV-drug users. In a 2002 survey, the prevalence of HCV-Ab was 6.3% among people with tattoos.

In China, the prevalence rate ranged from 1% in the region of lowest endemicity to 31.86% (3) in the region of highest endemicity. The prevalence in Iran's neighboring countries is 1.1% in Yemen (4), 1.8% Saudi Arabia (5), and 4% in Pakistan (6). In Iran, in the general population, the prevalence of HCV is 1% (7) and lower than upper countries. The prevalence of HCV infection in Iranian hemophilic patients was 15% in Fars, 44.3% in Kerman, 29.6% in Zahedan, 59.1% in Hamadan, 10 and 71.3% in Guilan. In another study, the prevalence of HCV in thalassemia patients was 19.3% (8).

A study conducted on hemodialysis patients showed a decreased prevalence of 4.5% for HCV-Ab in 2006 (9) compared to 14.4% in 1999 (9). Anti-HCV-Ab in Tehran dialysis patients was 19.5% (10, 11). A study conducted in 2013 on the general population of Mashhad (3870) showed Anti-HCV⁺ prevalence was 0.2% with ELISA and 0.3% with the PCR method (12).

2. Objectives

The aim of the study is to determine the prevalence and risk factors of HCV hepatitis among the general Birjand population.

3. Patients and Methods

This cross-sectional study was done to determine the prevalence of HCV in Birjand city. To determine the prevalence of HCV, 5,235 people were chosen, all older than 15 years, based on the cluster randomized method. The sampling method was a multistage kind, where 250 cluster heads were randomly chosen from the Birjand city post office, and from each head, 20 samples were chosen. From each head, 20 people in 5 age groups, from 15 to 69 years, were selected so that each age group included 2 women and 2 men. A checklist was designed according to the study variables and patients' blood sample results. After determining the population, the authors visited the patients' houses; after introduction of the study, permission and testimonials were obtained. The patients were invited to come for diagnostic HCV virus serology, and the data of blood sampling were given to them over phone. They were asked to come to the study center building on the day of the test. After the questionnaires were completed, risk factors for HCV were identified, including blood transfusion, familial history of HCV infection, or special encountering. Fasting blood samples of 5 cc were collected from each person and sent to a lab for determining the serology, and no anticoagulation substance was added. Sampling was done by skilled technicians at the site. The samples were transported to the lab immediately, and serums were stored in a freezer at -10°C until testing. After blood sampling, the titer and level of anti-HCV Ig was determined in each sample using HCV-Ab (DIA pro) ver. 4 enzyme immunoassay with a specificity of 99.5% and sensitivity of 100%. The test results and medical recommendations were given to the patients over the next 7 days. After specification of the test results, the data collection was done, and then data were entered into SPSS software by using statistical tests (percent, prevalence, and mean and standard deviation). To analyze the data, a chi-square test and Fisher's test in an alpha level of 0.05 were used. Odd ratio (OR) also was estimated.

4. Results

This study was performed on 5,232 people in Birjand city; 47.8% of them were male and 52.2% were female. The mean age was 39.7 ± 14.4 (ranging from 15 to 70) (Figure 1); 81.1% of patients were married and 16.7% were single; others were widowed or divorced (2.2%).

Among those with risk factors, 7% were smokers, 2.7% were non-IV-drug abuser addicts, 0.2% were IV-drug abusers, and 0.7% were addicted to alcohol. Familial history of HCV was seen in 0.4% of cases.

General prevalence of HCV (HCV-Ab) was 0.2% (10 cases). Among these, 6 patients (0.2%) were males and 4 were females (0.1%). Six patients (0.6%) had a primary school

degree, and 4 were about 25 to 34 years old, but there was no significant relationship between prevalence of HCV-Ab and age, sex, and education.

Four cases each had a history of going to a dentist or having major surgery, and 7 cases had a history of hospitalization for more than 10 days. However, no significant relationship was found between the prevalence of HCV-Ab and histories of blood transfusions, going to a dentist, having surgery or an endoscopy, alcohol drinking, Therapeutic bloodletting, or smoking ($P > 0.05$).

Seven cases were confirmed by PCR (5 cases were determined to be 3A, and 2 cases were 3B), so the prevalence of HCV (after PCR) was 0.14%, and the prevalence of HCV-Ab in non-IV-drug abuse addicts was 9.3 times more than in non-addict patients. In IV-drug abusers prevalence was 200 times higher. The prevalence of HCV-Ab patients with illicit sexual activities was 13.3 times more than in other patients without this risk factors, and prevalence among patients with a familial history of HCV infection was 26.3 times more than in other patients, which was significant ($P < 0.001$) (Figure 2).




Figure 1. The Prevalence of HCV Positivity According to Age Group




Figure 2. Comparison of HCV-Ab Positivity Among Risk Factors

5. Discussion

This study was conducted among 5,235 people to determine the prevalence and risk factors of HCV infection in Birjand city, the capital of South Khorasan.

HCV-Ab was detected by ELISA tests, which had positive rate of 0.2%, and the same was confirmed by PCR. Out of 10 patients (6 men and 4 women) who were HCV-Ab⁺ (0.2%), 7 patients (4 men and 3 women) were determined to be HCV-Ab⁺ with PCR (0.14%). The results showed that studies on the prevalence of HCV infection in Iran have mostly focused on high-risk people; for example, the study conducted by Alavian (2003) in the Iran Hemophilia Institute showed the prevalence of HCV-Ab was 60.2% (9).

There was no significant relationship found between HCV-Ab⁺ and sex, age, marriage, or kind and severity of bleeding disorder. The kind and numbers were determined by coagulative factors and familial history of hepatitis. Also, there was no relationship found between HCV-Ab⁺ and Hepatitis B Antigen positivity (HBS-Ag⁺), but the prevalence of HCV-Ab was significantly higher among HBS-Ag⁺ than HBS-Ag negative patients. In a study conducted in Tehran on 202 IV-drug abusers in 2006, the prevalence of HCV-Ab was 52%. During the nine years (1994–2008) of the study in Iran, 19.3% of the patients with thalassemia were HCV-Ab⁺. Also, 3.1% of immigrants were HCV-Ab⁺ (13). In a study conducted on IV-drug abusers in Hamedan, the prevalence of HCV-Ab was 31–47%, and was 31.5% among prisoner IV-drug abusers. Also, 45.4% of 460 prisoners were HCV-Ab⁺ in Gilan (7).

In a study conducted among 15,252 blood donors in 2003 in Kerman, 0.39% of them had a definite positive result for HCV, and there was no significant relationship found between HCV infection and age or marriage (14).

A study was performed by Alavian and Fallahian in 2009 (10) to determine the prevalence of HCV infection in Iran; it showed that the prevalence of HCV-Ab was about 15.6% in Iranian hemophils in Fars, 44.3% in Kerman, 29.6% in Zahedan, 59.1% in Hamedan, 71.3% in Guilan, and 50% overall in Iran (7).

Among dialysis patients in Tehran, the prevalence was 19.6%, and the prevalence of the disease become noticeably lower (from 14.5% in 1999 to 4.5% in 2006) in Iran (9). In other countries, the prevalence of the disease in special groups is higher. For example, in Vietnam, 29% of hemophilia patients were HCV-Ab⁺ in 2010 (15).

In a study conducted in Egypt in 2008, it was reported that the prevalence of HCV-Ab in blood donors was 26% (16), and a study done in Saudi Arabia on 1,214 patients suffering from viral hepatitis during 2005 showed that HBV infection is the most common type of viral hepatitis, and HCV, at 60.7%, is the second most common type (5).

A study in England showed that hemophilia patients with HCV-Ab were 83% in 1997, and were 84.28% in 1998. This number was 40% in the United States in 1999 (17).

A study conducted on 12,167 blood donors in Thailand in 2004 showed a HCV-Ab⁺ rate of 29% among them; in Eng-

land 7.8% of the donors were positive. Some studies have been conducted recently on the worldwide population. (18, 19) For example, a study to determine the epidemiology of HCV in 2014 showed that the prevalence of HCV-Ab is 2% for adults and 1.6% for all ages all over the world. The prevalence of viremia is 1.4% in adults and 1.1% in all ages.

China with 1.3%, Pakistan with 6.7%, Nigeria with 8.4%, Egypt with 14.7%, and Russia with 0.25%; and in total 25%, it has over half of the HCV-infected cases (20).

A study conducted on 3,870 people in Mashhad during 2012 that showed a prevalence of 0.2% for HCV-Ab, and that 0.13% of those were confirmed by PCR (12). The prevalence of HCV showed in this study is in accordance with the Mashhad and Iran studies.

In the authors' study, 52.2% of the population were female, 29.9% had a university degree, and there was no significant relationship found between HCV-Ab and age, sex, or education level ($P > 0.05$). Also, a significant relationship was found between HCV-Ab and risk factors such as blood transfusion, alcohol drinking, smoking, endoscopy, or surgery ($P = 0.2$).

Compared to non-addict patients, HCV-Ab was 200 times more prevalent in IV-drug abusers and 9.3 times more prevalent in non-IV-drug abusers ($P < 0.001$); also, prevalence was 13.3 times higher in patients with illicit sexual activities compared to patients with no such history ($P = 0.001$). The prevalence in patients with familial history of the disease was 26.3 times higher than in patients with no familial history ($P \leq 0.04$), and hence the relationship was significant.

HCV is among diseases that can be transferred by blood, IV-drug abusing, illicit sexual activities, and medical processes such as endoscopy, colonoscopy, or hemodialysis. Data gathered by checking and screening blood donors for HCV shows that IV-drug abusing is the most common way of transferring HCV infection, accounting for 60% of all chronic and new infections (1).

A study was conducted on 1,997 volunteers from June 2005 to November 2007 in Kuala Lumpur to determine the prevalence of HBV and HCV infection, which showed that 0.2% were HCV-Ab⁺ and 0.3% were both HCV-Ab⁺ and HBS-Ab⁺. Among those, 24.8% were IV-drug abusers, and 13% of the patients had a history of hepatitis (21).

Another study conducted on 884 volunteers in Bangladesh showed a prevalence of 22% for HCV-Ab, and IV-drug abuse was a risk factor in 60% (22). Further study among 6,917 patients in 2010 in Spain determined that of 195 patients with HCV-Ab⁺, 75.9% were positive based on PCR, and 75% were viremic (23). A similar study in 1995 involving 2,935 people in Australia showed that 86.4% of patients with HCV infection were IV-drug abusers (24).

In another study conducted in Bolivia in 2005, IV-drug abuse was an important risk factor for HCV, and 90% of patients with HCV had one of the following risk factors: (25) IV-drug abuse, sexual intercourse with infected peo-

ple, multiple partners, family history, Sexual transmitted disease (STD), and blood transfusion. Hence, IV-drug abuse is the most important risk factor, and other risk factors, such as medical procedures, are less frequent due to measures taken to prevent contamination. After IV-drug abuse, notable risk factors are illicit sexual activities and multiple sexual partners. A separate small study involved genotyping, but due to the small size of the sample, a relationship could not be determined between genotype and the risk factors and demographic specifications. Ten patients with HCV-Ab⁺ in this study included 5 patients between 25 and 34 years old. Patients with both HCV-Ab⁺ and PCR⁺ underwent genotyping; 4 patients out of 7 were 3a, and the other 3 patients were 3b.

Also, the patients had IV-drug abuse risk for HCV infection, which accompanies with genotype 3a in most of the studies (26). For example, a study conducted in 2007 in France showed that genotype 1a accompanies with transfusion risk, and genotype 3a accompanies with IV-drug abuse risk (27). In another study, most of the HCV infected patients younger than 45 years had genotype 3a, and other genotypes were seen in those older than 45 years. The increased prevalence of 3a patients in this study is in accordance with the above-mentioned studies (28).

The present of prevalence of HCV in Birjand city is lower than Iran's average, and prevalence of HCV infection is directly connected to IV-drug abuse.

Acknowledgments

We would like to thank all people of Birjand city in South Khorasan who helped us in conducting this study.

Footnotes

Authors' Contribution: Azade Ebrahimzadeh, Zohreh Azarkar, Masood Ziaee had roles in the design and conduct of the study; Gholamreza Sharifzadeh had a role in the analysis of the data; Azade Ebrahimzadeh wrote the manuscript; Zohreh Azarkar prepared the manuscript; Bita Bijari had a role in the analysis of the data.

Funding/Support: This study was supported by the Birjand University of Medical Sciences.

References

1. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. *Harrison's Principles of Internal Medicine*. 18th ed. United States: McGraw-Hill Education; 2012.
2. Mandell JE. *Principle and practice of infectious disease*. 8th ed. Churchill Livingstone: Elsevier; 2015.
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J Viral Hepat*. 2007;**14**(2):107-15. doi: 10.1111/j.1365-2893.2006.00785.x. [PubMed: 17244250]
4. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. *AIDS Suppl* 8:S39-46. doi: 10.1097/01.aids.0000304695.54884.4f. [PubMed: 18172390]
5. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. *Harm Reduct J*. 2006;**3**:26. doi: 10.1186/1477-7517-3-26. [PubMed: 16914042]
6. Al-Tawfiq JA, Anani A. Profile of viral hepatitis A, B, and C in a Saudi Arabian hospital. *Med Sci Monit*. 2008;**14**(1):CR52-6. [PubMed: 18160946]
7. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. *World J Gastroenterol*. 2009;**15**(45):5647-53. [PubMed: 19960560]
8. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. *Shiraz E Med J*. 2009;**10**(4):162-72.
9. Mohammad Alizadeh AH, Rezazadeh M, Ranjbar M, Fallahian F, Hadjilooi M, Mousavi M, et al. Frequencies of hepatitis B and C infections in hemophiliacs. *Pejouhesh*. 2006;**30**(2):119-23.
10. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proc Natl Acad Sci U S A*. 2010;**107**(33):14757-62. doi: 10.1073/pnas.1008877107. [PubMed: 20696911]
11. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. *Hemodial Int*. 2008;**12**(3):378-82. doi: 10.1111/j.1542-4758.2008.00284.x. [PubMed: 18638096]
12. Hajjani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroprevalence of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. *World J Gastroenterol*. 2006;**12**(30):4884-7. [PubMed: 16937474]
13. Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virus in mashhad, iran: a population-based study. *Hepat Mon*. 2013;**13**(3):e7723. doi: 10.5812/hepatmon.7723. [PubMed: 23745128]
14. Mirmomen S, Alavian SM, Hajarizadeh B, Kafae J, Yektaparat B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. *Arch Iran Med*. 2006;**9**(4):319-23. [PubMed: 17061602]
15. Delavari M, Tabatabaei SM. Frequency of hepatitis C and its related factors in blood donors in Kerman in 2003. *J A U M S*. 2004;**2**(2):323-58.
16. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Maz-zoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. *Gut*. 1999;**44**(6):874-80. [PubMed: 10323892]
17. Martins T, Narciso-Schiavon JL, Schiavon Lde L. [Epidemiology of hepatitis C virus infection]. *Rev Assoc Med Bras*. 2011;**57**(1):107-12. [PubMed: 21390467]
18. Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R, et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. *Hepatology*. 2006;**44**(2):341-51. doi: 10.1002/hep.21252. [PubMed: 16871571]
19. Thaikruea L, Thongsawat S, Maneekarn N, Netski D, Thomas DL, Nelson KE. Risk factors for hepatitis C virus infection among blood donors in northern Thailand. *Transfusion*. 2004;**44**(10):1433-40. doi: 10.1111/j.1537-2995.2004.04073.x. [PubMed: 15383015]
20. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. *Hepatology*. 2005;**42**(3):711-23. doi: 10.1002/hep.20836. [PubMed: 16116637]
21. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*. 2014;**61**(1 Suppl):S45-57. doi: 10.1016/j.jhep.2014.07.027. [PubMed: 25086286]
22. Muhlberger N, Schwarzer R, Lettmeier B, Sroczyński G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. *BMC Public Health*. 2009;**9**:34. doi: 10.1186/1471-2458-9-34. [PubMed: 19161623]
23. Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hos-sain L, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. *BMC Infect Dis*. 2010;**10**:208. doi: 10.1186/1471-2334-10-208. [PubMed: 20630111]

24. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. *Intervirology*. 2010;**53**(1):39–43. doi:10.1159/000252782. [PubMed: 20068339]
25. Hepatitis C Trust . *The Diagnosing viral hepatitis in the community*. England: 2010. Available from: <http://www.hepctrust.org.uk>.
26. Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. *Hepatol Res*. 2007;**37**(2):101–3. doi: 10.1111/j.1872-034X.2007.00015.x. [PubMed: 17300704]
27. Abergel A, Ughetto S, Dubost S, Bonny C, Aublet-Cuvelier B, Delarocque-Astagneau E, et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. *Aliment Pharmacol Ther*. 2007;**26**(10):1437–46. doi: 10.1111/j.1365-2036.2007.03530.x. [PubMed: 17900267]
28. Al-Sweedan SA, Jaradat S, Amer K, Hayajneh W, Haddad H. Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with β -thalassemia major. *Turk J Hematol*. 2011;**28**:47–51. doi: 10.5152/tjh.2011.05.

Archive of SID